Clinical Trial Update: Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating EGF816 in combination with selected targeted agents for EGFR-mutant non-small cell lung cancer; the study is currently active but not…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer

Drugs mentioned

• EGF816

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: EGFR-mutant Non-small Cell Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING